Home / Library / Do I qualify for tirzepatide? The criteria, decoded

Access · label rules vs insurance rules vs telehealth reality

Do I qualify for tirzepatide? The criteria, decoded

Published 2026-08-14 · 7 min read · By the research team · pending clinician sign-off

The BMI math and what counts as a comorbidity

BMI is weight in kilograms over height in meters squared — or the shortcut every calculator runs — and the two thresholds do the sorting: 30+ qualifies alone; 27–29.9 needs a documented companion condition. The companions that reliably count: hypertension (including controlled-on-medication), type 2 diabetes or prediabetes (an A1c of 5.7–6.4% is a qualifying finding many people don't know they have — worth a lab if you're near the line), dyslipidemia, obstructive sleep apnea (a sleep study is the documentation, and the OSA route is its own coverage door), established cardiovascular disease, and, prescriber-dependent, conditions like PCOS-with-metabolic-features or fatty liver disease. The documentation point matters more than people expect: "my blood pressure runs high" qualifies nothing; a chart reading or diagnosis does — so if you're at BMI 27–29.9, the highest-yield fifteen minutes is pulling your last labs and visit notes before any application. And BMI's known bluntness (muscular builds, body-composition edge cases) is real but mostly moot at the gate: the thresholds are how every system screens, and clinician judgment handles the edges.

The contraindications that end the conversation

Three absolute stops, none negotiable at any BMI. Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 — the boxed warning, rooted in rodent C-cell tumor findings; "family history" means asking your relatives a specific question before intake, not guessing (the thyroid explainer unpacks it). Prior serious hypersensitivity to tirzepatide. And pregnancy, planned or current, per the pregnancy rules. Below the absolute tier sits the caution tier — conditions that don't forbid but reshape the decision: pancreatitis history, significant gastroparesis, severe GI disease, diabetic retinopathy (for the diabetes lane), and gallbladder disease — each a real conversation where the honest telehealth question is whether a two-minute intake can actually have it. A program that asks about none of these has answered your quality question, per the clinician-audit section.

Three gatekeepers, three rulebooks

Insurance applies the strictest version: label criteria plus plan-specific requirements — documented lifestyle attempts, sometimes step therapy through cheaper drugs, occasionally supervised-program history — enforced through prior authorization (the PA playbook). Brand self-pay (LillyDirect) applies the label straight: a valid prescription confirming criteria, no insurer overlay, $299–449 for vials. Telehealth ranges from rigorous async review to checkout-flow theater; the label criteria plus a real medication and contraindication screen is the legitimate floor, and NexLife's published thresholds — BMI ≥27 standard, ≥23 marketed for its microdose tier — illustrate the market's spread, with the sub-27 microdose gate being looser than the label logic and worth understanding as such (our microdose audit applies). The strategic sequencing for a qualified patient: check insurance first (a covered $25–100 copay beats every cash price), Bridge eligibility if on Medicare, then brand self-pay versus verified compounded per the full route map.

If you don't qualify — and if you barely do

BMI under 27: the honest answer is that tirzepatide isn't indicated, programs marketing it to you anyway are selling past the evidence, and the adjacent legitimate paths are clinician-guided lifestyle treatment or, at 25–27 with metabolic findings, a real medical conversation about the full toolkit. Barely over the line at 27–30 with a qualifying condition: you're fully legitimate, and the practical notes are that insurers scrutinize this band hardest (documentation wins), that goal-setting matters more (a 20% average loss from BMI 28 lands somewhere the maintenance conversation should anticipate), and that the stopping criteria deserve as much thought as the starting ones — the plan for what "done" looks like, per the maintenance math, is best written before month one, not month twelve. Qualification, in the end, is the door; the treatment plan is the house.

The documentation kit: gather this before any intake

Qualification is mostly a paperwork race won in advance, so assemble the kit once. The measured baseline: a clinic-recorded height and weight within the last year — if you don't have one, a single primary-care or urgent-care visit creates it, and that visit can simultaneously generate half the list below. The lab set: most recent A1c or fasting glucose (the prediabetes finding at 5.7%+ is the most commonly missing qualifier), a lipid panel, and blood pressure readings — all standard annual-physical output, all worth requesting copies of through your patient portal today. The diagnosis list: your actual charted conditions with rough dates — "hypertension, diagnosed 2022, on lisinopril" is qualification language; "my pressure runs high" is not. The attempts narrative: a half-page you write yourself covering the last few years' real efforts — programs, apps, dietitian visits, gym stretches, what happened — which a clinician can reference into the chart note that satisfies most insurers' lifestyle-documentation demand. The family answers: the medullary-thyroid and MEN2 question actually asked of relatives, per the thyroid guide, plus your own pancreatitis/gallbladder history dates if any. The medication list with doses, because interactions screening is only as good as its inputs. Twenty minutes of assembly, and every gatekeeper in this article — insurer, brand program, telehealth intake — moves faster and rules in your favor more often.

Edge cases, adjudicated

The boundary questions that fill our inbox, answered as the systems actually treat them. High muscle mass at BMI 30+: BMI's bluntest failure — a genuinely muscular person can "qualify" while carrying little excess fat; ethically and clinically the drug isn't for you, most careful prescribers will say so, and the ones who won't are running checkout flows, not medicine. BMI 27–29.9 with borderline labs: the highest-yield move is completing the measurement — an actual A1c, an actual sleep study — because the difference between "probably prediabetic" and a charted 5.8% is the difference between denied and approved. Post-bariatric patients with regain: fully legitimate candidates and increasingly common ones, with the coordination caveat from the special-populations section — altered anatomy belongs under surgical or obesity-medicine oversight, not generic telehealth. Adolescents: tirzepatide's weight indication is adult-only as of this writing; pediatric obesity medicine has its own pathways and its own specialists, and any program selling to minors has disqualified itself. Age 65+: no upper age bar exists — qualification is unchanged — but the sarcopenia stakes, slower-ladder defaults, and Medicare's specific routes (the Bridge) shape the how. Normal-BMI "vanity" use: below every threshold, the label doesn't support it, the risk-benefit math inverts, and the microdose tiers marketed at BMI 23 are selling past the evidence — our audit of exactly that.

What the intake itself will look like — and how to read it back

Knowing the shape of a legitimate evaluation lets you grade the one you receive in real time. Expect: demographic and measured-weight capture; the full condition screen (thyroid family history, pancreatitis, gallbladder, GI disease, pregnancy status and plans); the complete medication list with specific attention to insulin, sulfonylureas, and oral contraceptives; goals and history; and — in better programs — baseline labs requested or recent ones reviewed. Expect the output to be a conversation or asynchronous exchange with an identifiable licensed clinician who can answer "why this dose, why this product," not an instant approval stapled to a checkout page. Now invert it: an intake that never asked the thyroid-family question, never saw your medication list, or approved you in the time it takes to read this paragraph has failed the audit from the safety guide — and since the documented clinical evaluation is also what makes 2026 compounding lawful, a fake evaluation isn't just a quality problem, it's a supply-continuity risk wearing a white coat. The empowering reframe: you're not only being evaluated at intake; you're evaluating, and the questions they fail to ask are the most informative answers you'll get.

After "yes": the first-90-days setup that qualification should trigger

Approval is the door, and walking through it well is a checklist most programs never hand you. Establish the baseline file the day you start: weight, waist, photos, the lab copies from your kit, and — if insurance is involved — confirmation that the baseline weight landed in a chart, because renewal criteria will demand response math against it. Set the monitoring cadence: the seven-day weight average, the strength benchmarks from the muscle guide, and a scheduled check-in rhythm with whoever prescribed. Pre-decide the checkpoints: what result by week twelve prompts what conversation, so the timeline's calibration does its job before anxiety does. And file the qualification kit rather than discarding it — the same folder serves every future prior authorization, program switch, appeal, and the eventual maintenance-phase conversations, which is the quiet lesson of this whole guide: in this system, the organized patient and the well-treated patient are usually the same person.

FAQ

What BMI do you need for tirzepatide?

BMI 30+, or 27+ with a weight-related condition such as hypertension, prediabetes, high cholesterol, or sleep apnea. Type 2 diabetes (Mounjaro) and OSA-with-obesity (Zepbound) are separate approved lanes.

What disqualifies you from tirzepatide?

Personal or family history of medullary thyroid carcinoma or MEN2, prior serious hypersensitivity to the drug, and pregnancy. Pancreatitis history and severe GI disease are caution flags requiring a real clinical conversation.

Can I get tirzepatide with a BMI of 26?

Not within label criteria — weight-management indication starts at 27 with a comorbidity. Programs marketing below that line are selling past the evidence; the legitimate path is a clinician conversation about the full toolkit.

Related: Every way to get it, priced · Prior authorization playbook · The thyroid warning explained · Sleep-apnea coverage door

Educational content, not medical advice — dosing, switching, and side-effect decisions belong with your prescriber. Sources and trial citations: the source library. Corrections within 48 hours: policy.